NCT02049411View on ClinicalTrials.gov

Ketamine and Changes of the Short Portable Mental Status Questionnaire

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

May 31, 2014

Conditions
Postoperative Cognitive Dysfunction
Interventions
DRUG

Ketamine

Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.

DRUG

physiological solution

physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.

Trial Locations (1)

06720

Centro Medico Nacional Siglo XXI. UMAE Hospital de Especialidades, Mexico City

All Listed Sponsors
collaborator

National Polytechnic Institute, Mexico

OTHER

lead

Instituto Mexicano del Seguro Social

OTHER_GOV

NCT02049411 - Ketamine and Changes of the Short Portable Mental Status Questionnaire | Biotech Hunter | Biotech Hunter